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Abstract  The aim of the thisstudy was to investigate the ozone dosage required to remove 
active pharmaceutical ingredients (APIs) from biologically treated wastewater of varying 
quality, originated from different raw wastewater and wastewater treatment processes.  
Secondary effluents from six Swedish wastewater treatment plants (WWTP) were spiked 
with 42 APIs (nominal concentration 1μg/L) and treated with different O3 doses (0.5-12.0 
mg/L ozone) in bench-scale experiments.  
In order to compare the sensitivity of APIs in each matrix, the specific dose of ozone required 
to achieve reduction by one decade of each investigated API (DDO3) was determined for 
each effluent by fitting a first order equation to the remaining concentration of API at each 
applied ozone dose. Ozone dose requirements were found to vary significantly between 
effluents depending on their matrix characteristics. 
The specific ozone dose was then  normalized  to the dissolved organic carbon (DOC) of each 
effluent. The DDO3/DOC ratios were comparable for each API between the effluents. 
15 of the 42 investigated APIs could be classified as easily degradable (DDO3/DOC≤0.7), 
while 19 were moderately degradable (0.7<DDO3/DOC≤1.4), and 8 were recalcitrant towards 
O3-treatment (DDO3/DOC >1.4). Furthermore, we predict that a reasonable estimate of the  
ozone dose required to remove any of the investigated APIs may be attained by multiplying 
the experimental average DDO3/DOC obtained with the actual DOC of any effluent. 
Keywords: matrix effect; ozonation; ozone dose, pharmaceuticals; wastewater.  
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1. Introduction 
The modern life-style of developed countries involves daily usage of artificial compounds 
such as active pharmaceutical ingredients (API), personal care products, hormones, pesticides 
and other environmentally persistent chemicals. As a result residues of these compounds 
become micropollutants in wastewater (Fick et al., 2010; Hollender et al., 2009; Richardson, 
2010; Gerrity and Snyder, 2011; Huber et al., 2005; Richardson, 2010). Of all groups of 
micropollutants the vast majority of research activities are currently focused on the fate of 
active pharmaceutical ingredients during wastewater treatments (Hollender et al., 2009; 
Huber et al., 2003; Huber et al., 2005; Lee and von Gunten, 2010; Zimmermann et al., 2011; 
Fick et al., 2011; Falås et al., 2012a, 2012b). APIs by purpose are generally designed to illicit 
a specific biological action. Due to their use pattern, release to the environment is mainly via 
sewage outlets into surface waters. APIs are usually found at concentrations ranging from 
pg/L- μg/L in wastewater and surface waters influenced by wastewater outlets. However,  
chronic exposure of APIs to humans and wildlife even at these low concentrations is both of 
scientific and societal concern (Richardson, 2010).  
To address this problem many WWTPs consider incorporating an additional treatment 
process step to remove APIs from the effluent. Treatment with O3 appears to be one of the 
most promising technologies for the removal of these compounds (Ternes et al., 2003. 
Hansen et al., 2010; Hollender et al., 2009; Huber et al., 2003; Huber et al., 2005; Lee and 
von Gunten, 2010; Zimmermann et al., 2011).  
One of the first studies which showed the efficiency of ozonation for removal of 
micropollutants in biological treated wastewater was by Ternes et al. (2003). Ozonation was 
employed at 5.0 to 15.0 mg/L of O3 to investigate the removal efficiency (Ternes et al., 2003) 
for selected APIs, personal care products and iodated X-ray contrast media. Pharmaceuticals 
and personal care products were removed sufficiently by only 5 mg/L of O3 while the iodated 
X-ray contrast media were only partially removed by 15 mg/L of O3. However, as there is not 
much toxicological concern for iodated X-ray contrast media results were interpreted as 
promising and more optimised treatment studies were conducted which reported efficient 
removal of pharmaceuticals and hormones in wastewater at lower O3 doses (2.0-3.5 mg/L) 
(Bahr et al., 2007; Hansen et al., 2010; Huber et al., 2005). Estimating the removal 
efficiencies of APIs from wastewater effluents in bench and pilot scale experiments, was the 
main focus of subsequent studies (Hollender et al., 2009; Huber et al., 2003; Zimmermann et 
al., 2011). For example, Hollender et al. (2009) studied the removal efficiencies of 220 
pharmaceuticals in full scale with conventional activated sludge sewage treatment followed 
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by ozonation and sand filtration. Kinetic studies and modeling of ozonation based on reactor 
hydraulics, O3 chemistry and reaction kinetics were also performed for a full scale municipal 
wastewater facility (Zimmermann et al., 2011).  
Generally, APIs and other micropollutants are easy to degrade, i.e. can be removed with 
low ozone dosage, if they react reasonable fast with molecular ozone. If a micropollutant 
does not react well with ozone it will still degrade with higher applied ozone dosage via a 
secondary oxidation mechanism by which O3 in water is converted to the hydroxyl radical, 
HO, which is very reactive (non-selective) to most organic molecules.  
   Up to now, the parameter most commonly used by researchers to determine how well 
an API reacts with O3, is the second order rate constant with O3 (kO3,API , selective oxidation) 
and HO (kHO,API, non-selective oxidation) (Hollender et al., 2009; Huber et al., 2003; 
Zimmermann et al., 2011). According to these studies, compounds with kO3,API greater than 
104 M-1s-1, require low delivered O3 doses (easily degraded). Compounds with kO3,API < 104 
M-1s-1, are more persistent to O3 treatment and therefore their degradation occurs mainly via 
reaction with HO,  the secondary degradation route of ozonation.  
However, of the several hundred APIs which have been detected in WWTP effluents 
(Ternes et al., 1998; Kolpin et al., 2002; Hollender et al., 2009; Fick et al., 2011; Falås et al., 
2012) very few have had their respective kO3,API  and kHO,API  determined (Benner and Ternes, 
2009; Buffle et al., 2006a; Dodd et al., 2006; Huber et al., 2003; Huerta-Fontela et al., 2011). 
In fact, constants are available for less than 10% of the model APIs used in this study (Table 
S2). Even when these two rate constants (kO3,API and kHO,API ) are known for an API, an 
experiment to determine the ozone and HO exposure that results from an ozone dose in the 
specific wastewater is needed before the degradation of the API can be predicted (Huber et 
al., 2005; Buffle et al., 2006b). 
With O3 production being an energy intensive process  (Kim and Tanaka, 2011), it is 
important for WWTPs to use optimum O3 doses that achieve sufficient API degradation 
while maintaining low operational cost (Bahr et al., 2007; Hansen et al., 2010). APIs exhibit 
different susceptibilities to O3 degradation which can vary up to 10 orders of magnitude 
(Hoigne and Bader, 1983; Hollender et al., 2009; Huber et al., 2003). They are also 
competing for O3 degradation with the organic components found in the matrix of the WWTP 
effluent (Hollender et al., 2009) that vary in amount and quality depending on the treatment 
process and origin of wastewater. This makes it particularly difficult to predict the required 
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O3 dosage requirements (DO3) for satisfactory API removal in WWTP effluents, which is a 
crucial parameter in estimating treatment design and therefore cost. 
Therefore, this study aimed to unveil a more direct approach to describe the removal of 
pharmaceuticals in wastewater effluents, which could also be used to predict the required O3 
dose for 90% removal of a specific pharmaceutical in a wastewater, solonly based on simple 
water quality parameters. To achieve this, the required delivered O3 dose (0.5 mg/L ≤ DO3 ≤ 
~12 mg/L) to achieve one order of magnitude removal of 42 APIs (at low concentrations, 
μg/L, Table S2) from 6 Swedish WWTP effluents, were investigated. These APIs are 
commonly found in the WWTP effluents of Sweden (Fick et al., 2011, 2012; Falås et al., 
2012a) and have different susceptibilities to ozonation (Benner and Ternes, 2009; Buffle et 
al., 2006a; Dodd et al., 2006; Hoigne and Bader, 1983; Huber et al., 2003).  
Effluents used in the experiments were chosen to represent typical variations observed in 
the main traditional characteristics of effluent quality that would occur due to different 
treatment processes currently employed in Sweden and also variability in raw water, i.e. 
COD, alkalinity and N-NH4+ content (Table 1).  
As API’s begin to react with O3, they are also competing with the matrix components of 
the effluent for O3 degradation, therefore this study attempted to correlate the DO3 with the 
effluent characteristics.  
 
2. Materials and Methods 
2.1 Chemicals 
All pharmaceutical reference standards were of analytical grade (>98%) purchased from 
different suppliers (Table S3). A stock solution of the APIs was prepared in methanol 
(Merck, Darmstadt, Germany) at concentration of about 100 mg/L.  The experimental set-up 
for the ozonation was based on a 1.0 g/h ozone generator from O3-Technology AB,Vellinge, 
Sweden, which was supplied with dry oxygen gas. The generated O3 was dispersed though a 
diffuser in a collection bottle containing Milli-Q water. The later one was immersed in an 
icebath sot that  O3 solubility is increased. Based on these experimental conditions, the 
concentration of O3 in the stock solution was between 30 and 40 mg/L. Further details are 
found in Antoniou and Andersen (2012).   
2.2 Wastewater effluents 
Effluents from five WWTPs in Sweden, including Källby (Effluent 1&2), Björnstorp 
(Effluent 3), Oresundsverket (Effluent 4), Sjölunda (Effluent 5), and Nykvarnsverket 
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(Effluent 6) were used in this study. Effluent 1 and Effluent 2 were from the same treatment 
plant but were collected on separate occasions with a 3 week time interval. Although Effluent 
1 and Effluent 2 come from the same WWTP, they were treated as 2 different effluents due to 
the variability of their characteristics. This difference is attributed to the significant rainfall 
events which occurred following the first sampling event. Continues rainfall most likely 
caused a sludge wash-out, reducing the biological treatment efficiency and increasing the 
COD value, while at the same time alkalinity value reduced because of dilution with the rain 
water. The characteristics and treatment processes that are performed at each WWTP are 
listed in Table 1 and extensively described in S.I., respectively. As nitrification was well 
functioning in all WWTPs, the measured concentration of nitrite in the effluents was below 
0.1 mg/L. 
Table 1. Source and characterization of the wastewater effluents. 
WWTP Källby 1 Källby 2 Björnstorp Öresundsverket Sjölunda Nykvarnsverket 
Eff1 Eff2 Eff3 Eff4 Eff5 Eff6 
COD, mg/L 29 51 30 36 90 44 
DOC, mg/L 7.5 6.5 5.2 8.1 13.7 8.4 
Alkalinity, mg HCO3-/L 244 154 185 229 256 164 
pH 6.6 6.7 7.0 7.2 6.7 6.8 
N-NH4+, mg/L 1.36 2.98 0.77 4.93 1.86 5.98 
SUVA, (L/mg)/m  2.74 2.94 2.07 2.10 1.86 2.01 
A254, cm-1  0.206 0.190 0.107 0.171 0.256 0.168 
 
2.3 Experimental set-up 
Effluent was spiked with the APIs standard to give a nominal concentration of 1 µg/L, and 
then transferred into borosilicate glass vials, where different volumes of O3 stock solution 
were added (in triplicate) to give nominal concentrations between 0.5 and <12 mg/L O3 for a 
total volume of 150 mL. Vials were then placed in a covered waterbath at 15C for at least 10 
hours which is significantly more than the lifetime of O3 in wastewater. The doses of O3 
delivered in each experiment varied (~5% relative standard deviation, RSD) since the 
concentration of O3 in the stock solution was variable between days, but the delivered O3 
dose to the vials was quantified exactly by adding the same volume of ozone stock solution to 
vials prepared with indigo trisulfonate solutions as was added to the effluents. The loss of 
indigo trisulfonate is proportional to the O3 mole to mole. Further details of the ozonation 
procedure and quantification is given in Antoniou and Andersen, 2012. Over several method 
evaluation performed in parallel to the experiments using each time several vials prepared 
with indigo trisulfonate solutions the repeatability of the added O3 dose was always better 
than 5% RSD.  
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2.4 Analysis 
DOC, pH, alkalinity (mg HCO3-/L), COD, and NH4+ concentrations in the effluent were 
quantified based on standard methods. UV-absorbance at 254 and 272 nm was measured 
before and after ozonation with a Varian CARY 50Bio UV-Vis spectrophotometer. Specific 
UV-absorbance (SUVA) was determined by dividing the sample absorbance at λ=254 nm 
with the corresponding DOC value. The specific O3 dose delivered (DO3) was measured with 
the colorimetric method of indigo (λ = 600nm), by preparing bottles with indigo trisulfonate 
solution in Milli-Q water in parallel with the treatment samples (Antoniou and Andersen, 
2011; Bader and Hoigne, 1981). After SPE extraction, the APIs were quantified by 
LC/MS/MS using a triple-stage quadrupole mass spectrometer (MS/MS TSQ Quantum Ultra 
EMR) coupled to an Accela LC pump (both from Thermo Fisher Scientific, San Jose, CA, 
USA) and a PAL HTC autosampler (CTC Analytics AG, Zwingen, Switzerland) with a 
Hypersil GOLD aQTM column (50 mm x 2.1 mm ID x 5 µm particles). The same method was 
used to investigate the fate of APIs in wastewater treatment by Hörsing et al. (2011) and Hey 
et al. (2012) and a full method evaluation and detailed description is given in Grabic et al. 
(2012).  
 
2.5 Data treatment 
In order to determine the O3 dose that achieved 90% removal of each API in every effluent, 
the removal rate achieved with each O3 dose in each effluent were fitted with Equation 1. 
Equation 1 is an exponential formula that describes the remaining API concentration in 
relation to its initial concentration after a specific O3 dose is delivered (DO3). It is dependent 
on the fact that ozone’s fate in the effluent is determined by the effluent’s matrix and not 
significantly affected by the reaction with the APIs; therefore is independent from the APIs 
concentration. The equation contains the O3 dose required to remove 90% of the API as a 
constant (here noted as decadic dose of O3 DDO3), allowing determination of the standard 
error directly through curve fitting.  The fitted parameter is named the decadic dose of O3, 
DDO3.  








3
3
10log)1.(
3
3 DDO
DO
o
o
CC
DDO
DO
C
CEq
 
Equation 1 resembles the general formula used for the characterization of the effectiveness of 
energy intensive advanced treatment methods (Equation 2) recommended by IUPAC and 
described by Bolton et al. (2001). Equation 2 correlates the electrical energy dose (EED) with 
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the residual concentration of the treatment target compound and uses the constant EEO which 
is the EED required to achieve 90% removal (Bolton et al., 2001). 
EOo E
EED
C
C
Eq 



log)2.(
 
Equation 1 was suggested by Hansen et al., (2010) who used both Equations 1 and 2 to 
describe the effectiveness of O3 treatment for estrogenic chemicals in WWTP effluents in 
terms of the O3 and energy dosage applied. Based on the above, it was decided to use the 
same system of equations to describe the effectiveness of O3-treatment for API removal from 
wastewater. Data treatment (determination of DDO3) was conducted in GraphPad Prism 5. 
3. Results and Discussion 
3.1  Removal of APIs from 6 WWTP effluents: Effect of wastewater matrix 
In this study, 42 APIs commonly found in WWTP effluents in Sweden were spiked in six 
different WWTP effluents and treated with O3 to evaluate their removal efficiencies and the 
effect of the matrix. Figure 1 summarizes the contribution of each O3 dose (0.5 to ~12.0 mg/L 
O3) on the removal of the APIs in each one of the six WWTP effluents. The order with which 
APIs appear in the x-axis is with declining order of percentage removal achieved with the 
lowest O3 dose. The same data is also shown in Figure 2 (few examples) and Figures S1 to 
S6, but plotted in a less condensed manner allowing representation of experimental variation. 
A general trend can be seen whereby increasing O3 dosage increases API removal efficiency 
(Figure 1). However, great variability is observed in required O3 dose to achieve removal of 
different APIs within the same effluent and for the same API between effluents.  
For the lowest delivered O3 dose (0.5-0.6 mg/L), Effluent 1 and Effluent 3 had the 
highest number of APIs exhibiting removal efficiencies between 50-100%, possibly due to 
their low COD values compared to other effluents. Low COD values reduce the competition 
for O3 between APIs and organic matter of the matrix required for degradation. The high 
alkalinity value observed in Effluent 1(highest in the group, Table 1) did not seem to 
significantly affect API removal. However, APIs in Effluent 5 appear to be the most 
recalcitrant to O3 treatment, with all exhibiting <50% removal at the lowest delivered O3 
dosage. A significant increase in O3 dosage to ~8.9 mg/L, had little effect on API removal in 
Effluent 5 compared to the other effluents, since only 18 out of 42 were removed by levels 
greater than 90%. It is believed that both high COD (~90 mg/L) and alkalinity (~250 mg 
HCO3-/L) levels present in Effluent 5 contributed to inhibiting the API removal. 
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Figure	1:	Profiles	of	dose	dependency	for	the	removal	of	pharmaceuticals	in	the	6	investigated	wastewaters.	 
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Overall, all APIs in Effluents 2, 3, and 6 were removed by over 50% at the highest O3 
dosage. In Effluents 1 and 4, only 1 API had less than 50% removal, while 7 APIs were 
poorly removed (< 50%) in Effluent 5 even at the highest O3 dosage.  
Based on the results shown in Figure 1, an APIs’ susceptibility to O3 degradation appears to 
be highly dependent on the type of wastewater used, explaining the wide range of removal 
efficiencies that some APIs exhibited in this study. Specifically, the synthetic steroid 
beclomethasone was removed between 0-98% in the 6 effluents. Removal of fluconazole 
(antifungal) and flutamide (antiandrogen) ranged between 33-77% and 13-87%, respectively, 
inferring that some APIs were not effectively degraded (to reach the treatment goal of 90%) 
in any of the tested- effluents with the applied O3 doses.  
A 
       
B 
 
 
Figure 2: Concentration profiles for selected APIs in different WWTP effluents, which follow 
first order decay with the delivered O3 dose (DO3) (A) or exhibiting an apparent lag-phase 
(B). The intersect of the black horizontal line with the 10 % remaining API concentration (y-
axis) indicates the corresponding DDO3. T-bar represent standard deviation with n=3. 
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   3.2 Required ozone dose to achieve 90% removal of API in WWTP effluents 
In order to determine the O3 dosage that achieving 90% removal of each API in every 
effluent, the data shown on Figure 1 were fitted with Equation 1. For each API and effluent 
there are 3 results of each O3 dose applied that stems from the triplicate O3 addition which are 
fitted as independant points. Selected fitting curves are shown in Figure 2 and all the curves 
for the 42 APIs in the 6 effluents are shown in Figures S1-S6.  
In this study, at lower O3 doses an apparent lag-phase towards degradation was observed 
for some APIs and it wasn’t until higher O3 doses were applied that degradation occurred 
(Figure 2B). Once the O3 lag-phase dose was surpassed, a decrease  of APIs concentrations 
was observed as DO3 increased which is  similar to the curve shape (exponential decay) for 
APIs which did not show this lagphase. It is our belief, that the lag-phase is a result of the 
low reactivity of some APIs for direct reaction with O3 in addition to the competition with the 
wastewater matrix for O3 degradation.  Some of the matrix components react directly with O3 
and quickly consume the low O3 doses, therefore reducing the chances of O3 reacting with the 
target compounds. It is only when O3 is added at higher doses than required to satisfy the O3 
reactive part of the matrix, that enough O3 remains for the recalcitrant APIs to be degraded 
either directly or through the secondary pathway which is mediated by HO (O3 + H2O  
2HO + O2), assuming O3 remains in the wastewater long enough to convert to the radical 
form. To fit the concentration curves of APIs that showed apparent lag of reactivity towards 
low O3 doses, a variation of Equation 1 was developed and shown as Equation 3 (see Figure 
S7 for graphical representation).    
3333
33
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The resulting estimated DDO3 values of each API in all the effluents are presented in 
Table 2. Significant variation is observed in the DDO3 values of a specific API depending on 
the wastewater effluent matrix. For example, carbamazepine exhibited a low DDO3 of ~2 
mg/L in Effluent 3, compared to the high DDO3 of ~ 10 mg/L in Effluent 5. This confirms the 
strong influence exerted by the wastewater matrix components on APIs removal efficiencies 
with O3. This has also been observed by Benitez et al. (2009) during O3-treatment of 
pharmaceuticals (including metoprolol and naproxen) in surface and ground water and 
wastewater. Their results showed higher pharmaceutical removal in surface water 
(alkalinity=30 mg CaCO3/L) compared to groundwater (alkalinity=388 mg CaCO3/L), while  
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Table 2: Ozone dose for removal of the first decade of each pharmaceutical in each 
wastewater and the dose relative to the DOC . (NA* = compound not quantified due to 
chromatographic shift of peak outside of the MS window; NA** = out of range, either 
<<lowest dose or >> highest dose of ozone applied) 
DDO3 (ppm O3) [DDO3/DOC] 
API Eff1 Eff2 Eff3 Eff4 Eff5 Eff6 Eff1 Eff2 Eff3 Eff4 Eff5 Eff6 Ave
Easily degradable 
Repaglinide  2.6 3.7 1.8 4.1 8.7 1.5 0.35 0.57 0.35 0.50 0.64 0.18 0.43 
Ezetimibe  3.2 4.6 1.5 3.8 8.0 2.0 0.43 0.71 0.29 0.47 0.58 0.24 0.45 
Diltiazem 3.6 3.7 2.2 4.3 8.0 3.9 0.48 0.57 0.42 0.53 0.58 0.47 0.51 
Eprosartan  3.2 4.9 1.9 4.5 9.1 4.2 0.43 0.76 0.37 0.55 0.66 0.50 0.55 
Trimethoprim  4.0 4.3 2.1 4.4 9.7 3.9 0.53 0.67 0.40 0.54 0.71 0.47 0.55 
Clomipramine  2.3 7.3 2.4 3.7 7.5 4.2 0.31 1.13 0.46 0.45 0.55 0.50 0.57 
Risperidone  3.5 4.7 0.9 5.5 12.1 5.0 0.47 0.73 0.17 0.68 0.88 0.60 0.59 
Hydroxyzine 3.4 5.7 1.9 4.8 10 4.8 0.45 0.88 0.37 0.59 0.73 0.57 0.60 
Codeine 4.2 4.9 2.4 4.6 9.2 5.4 0.56 0.76 0.46 0.57 0.67 0.65 0.61 
Carbamazepine 5.1 5.4 2.2 4.3 10.8 3.5 0.68 0.84 0.42 0.53 0.79 0.42 0.61 
Naproxen 5.7 5.0 2.5 6.4 10 3.7 0.76 0.77 0.48 0.79 0.73 0.44 0.66 
Fexofenadine 5.2 5.8 3.0 6.5 9.1 2.9 0.69 0.90 0.58 0.80 0.66 0.35 0.66 
Orphenadrine  4.5 5.0 3.4 4.8 12.1 4.0 0.60 0.77 0.65 0.59 0.88 0.48 0.66 
Diclofenac  4.7 5.8 NA* 3.5 10 NA* 0.63 0.90 NA* 0.43 0.73 NA* 0.67 
Cilazapril 4.5 7.1 2.7 5.7 11 4.0 0.60 1.10 0.52 0.70 0.80 0.48 0.70 
Moderately degradable 
Loperamide  2.0 4.5 <0.5 5.7 13.3 8.7 0.27 0.70 NA** 0.70 0.97 1.04 0.74 
Glimepiride 7.0 7.6 3.6 6.7 >>8.9 0.6 0.93 1.18 0.69 0.82 NA** 0.07 0.74 
Rosuvastatin 5.4 5.6 3.3 5 14.5 4.8 0.72 0.87 0.63 0.61 1.06 0.57 0.74 
Haloperidole 4.8 7.8 1.5 6.3 11.8 5.9 0.64 1.21 0.29 0.77 0.86 0.71 0.75 
Sulfamethoxazole 4.8 4.5 3.6 4.5 17.6 NA* 0.64 0.70 0.69 0.55 1.28 NA* 0.77 
Verapamil NA* 5.4 <0.5 5.0 10.5 7.5 NA* 0.84 NA** 0.61 0.77 0.90 0.78 
Tramadole  5.7 5.8 3.4 6.3 13 6.4 0.76 0.90 0.65 0.77 0.95 0.77 0.80 
Citalopram 5.0 7.8 2.0 7.1 15 5.0 0.67 1.21 0.38 0.87 1.09 0.60 0.80 
Sertraline 6.4 5.2 1.7 7.9 12 11.6 0.85 0.81 0.33 0.97 0.88 1.39 0.87 
Venlafaxine  5.3 6.3 3.4 6.4 16.6 9.3 0.71 0.98 0.65 0.79 1.21 1.11 0.91 
Maprotiline  7.3 6.9 4.1 8.3 13.6 7.2 0.97 1.07 0.79 1.02 0.99 0.86 0.95 
Bisoprolol  7.2 6.0 3.3 7.3 21 7.2 0.96 0.93 0.63 0.90 1.53 0.86 0.97 
Amitriptyline  7.3 9.4 3.6 8.3 13.6 7.3 0.97 1.46 0.69 1.02 0.99 0.87 1.00 
Metoprolol  6.9 6.9 3.8 7.4 18.2 8.8 0.92 1.07 0.73 0.91 1.33 1.05 1.00 
Biperiden  5.9 6.3 4.3 7.3 23 7.4 0.78 0.98 0.83 0.90 1.68 0.88 1.01 
Levonorgestrel  6.7 7.3 6.6 6.0 18.2 6.5 0.89 1.13 1.27 0.74 1.33 0.78 1.02 
Fluoxetine 6.6 6.8 3.1 7.7 20 11.3 0.88 1.05 0.60 0.95 1.46 1.35 1.05 
Irbesartan  8.7 7.7 5.4 11.5 13.7 4.3 1.16 1.19 1.04 1.41 1.00 0.51 1.05 
Bupropion  8.1 8.0 5.2 9.3 >>8.9 12.1 1.08 1.24 1.00 1.14 NA** 1.45 1.18 
Recalcitrant towards ozone degradation 
Oxazepam  12.3 11.3 7.1 13.5 18.4 9.7 1.64 1.75 1.37 1.66 1.34 1.16 1.49 
Ketoprofen  13.4 12.7 5.5 13.2 23.9 9.7 1.78 1.97 1.06 1.62 1.74 1.16 1.56 
Memantine 11.4 12.8 7.8 14.5 21.3 10.2 1.52 1.98 1.50 1.78 1.55 1.22 1.59 
Ibuprofen 11.5 10.9 7.3 14.7 27 10.4 1.53 1.69 1.40 1.81 1.97 1.24 1.61 
Beclomethasone  20 18 5.8 12 >>8.9 9.2 2.66 2.79 1.12 1.47 NA** 1.10 1.83 
Atracurium  3.7 6.2 4.4 11 11.1 3.9 0.49 3.13 0.85 1.35 0.81 0.47 1.18 
Flutamide >>10.2 25 11.7 17.9 >>8.9 9.4 NA** 3.87 2.25 2.20 NA** 1.12 2.36 
Fluconazole  15.1 18 10.7 20 >>8.9 22 2.01 2.79 2.06 2.46 NA** 2.63 2.39 
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the effluent containing the lowest DOC and alkalinity had the highest removal among the 
3 secondary effluents tested (Benitez et al., 2009). 
Based on the above, and in order to categorize the different pharmaceuticals into easily 
degradable, moderately degradable and recalcitrant towards O3 degradation, the Specific 
DDO3 value was calculated. Specific DDO3 is calculated by dividing the DDO3 by the 
effluent DOC [DDO3/DOC]. The selection criterion for an API to be characterized as easily 
degraded was decided to be a [DDO3/DOC] value of ≤ 0.7. Fifteen out of 42 investigated 
APIs fulfilled this criterion including repaglinide (antidiabetic), trimethoprim (antibiotic), 
carbamazepine (antiepileptic) and diclofenac (antiphlogistic) and naproxen (antiphlogistics). 
Nineteen APIs fulfilled the moderately degradable criterion of 0.7 < [DDO3/DOC] ≤ 1.4 
including sulfamethoxazole (antibiotic), metoprolol and bisoprolol (beta blockers) and 
citalopram, amitriptyline, maprotiline, venlafaxine, fluoxetine, bupropion and sertraline 
(antidepressants). The remaining 8 APIs, such as beclomethasone and the antiphlogistics 
ketoprofen and ibuprofen, were considered O3-recalcitrant since they had [DDO3/DOC] >1.4.  
 
Previous studies of the cited literature (Hollender et al. 2009; Bahr et al.,2010)  have also 
used the O3 dose in relation to the DOC wastewater value to describe the treatment 
efficiency. In a study conducted by Hollender et al. (2009) on the removal of organic 
micropollutants from wastewater with O3, which included 24 pharmaceuticals, the fast 
reacting APIs sulfamethoxazole, diclofenac, carbamazepine and trimethoprim were 
eliminated at a dose of 0.47 g O3/g DOC (dissolved organic carbon). In our study we found 
that the same compounds require from 0.55 up to 0.77 g O3/g DOC for 90% removal. 
Furthermore, Bahr et al., (2010) reported complete removal of naproxen, diclofenac and 
carbamazepine at a specific ozone dose of 0.5 g O3/g DOC during ozonation of secondary 
WWTP effluent. Our study predicts the dosage required for 90 % removal of these APIs to be 
in the order of 0.61-0.66 g O3/g DOC. While for slow reacting compounds, such as ibuprofen 
and ketoprofen, a specific ozone dose > 1 g O3/g DOC is required for > 95% removal 
according to Bahr et al., 2010. In comparison, our work showed the dosage of ozone required 
for 90 % removal to be 1.61 and 1.51 g O3/g DOC, respectively, for these two APIs. 
The degradation profiles of select APIs in the 6 effluents that follow first order decay 
with the added O3 (carbamazepine, naproxen) are shown in Figure 2A while Figure 2B 
depicts the degradation profiles of the APIs that exhibited an apparent lag phase before any 
significant degradation occurred (beclomethasone, memantine). Intersection of the horizontal 
line with the y-axis in Figures 2 and S1-S6 indicates the DDO3 of the APIs from which it is 
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evident that Effluent 5 is the most recalcitrant to O3-treatment as it requires the higher DDO3 
for all APIs compared to the other effluents (Figures 2A and 2B).  
Based on the data shown in Table 2, the average [DDO3/DOC] for the majority of the 
APIs is ≤ 1.2, while only a few exhibit a [DDO3/DOC] > 1.5. Thus, an O3 dose of 1.4 g per g 
DOC should be sufficient to remove (by at least 90%) more than 80% of the APIs tested in 
this study. However, in order to remove the most O3-recalcitrant APIs as well, a twice as high 
O3 dose ([DDO3/DOC]> 2.4 g O3 per g DOC) is needed which results in a significantly more 
costly treatment process. 
 
3.3 Effect of chemical structure of APIs on O3 reactivity  
The chemical structure of each API and the functional groups comprising it determine 
whether an API would be easy or difficult to degrade with O3. Due to its electronic 
configuration, O3 can perform different types of reactions in water including oxidation 
reactions, cycloadditions and electrophilic substitution reactions (Beltrán, 2004). Easily 
degradable APIs (relatively low [DDO3/DOC] values) are characterized by the presence of 
electron-rich functional groups and they mainly react readily with O3 through electrophilic 
substitution. These functional groups include C=C double bonds (found in eprosartan, 
carbamazepine), tertiary amines (repaglinide, clomipramine), aniline (dicofenac), phenol 
(iezetimibe) and methoxy groups (trimethoprim, diltiazem, naproxen) (Hoigne and Bader, 
1976; Huber et al., 2003; Huber et al., 2005;  Nakada et al., 2007, Hollender et al., 2009). 
APIs which are poorly removed (relatively high [DDO3/DOC] values) generally contain 
electron-withdrawing functional groups, such as fluoro (flutamide, fluconazole), nitro 
(flutamide), chloro (beclomethasone), amide (flutamide) and carboxyl (ibuprofen, 
ketoprofen) (Hey et al., 2012; Nakada et al., 2007; Acero et al., 2000; Hollender et al., 2011). 
Electron withdrawing groups reduce e- density from the APIs structure inhibiting 
electrophilic substitution reactions from occurring. In addition, the electronegative groups 
themselves are less likely to react with O3 and thus cause a shielding effect. 
Some easily degradable APIs such as carbamazepine and diclofenac also contain 
electron-withdrawing functional groups (amide in carbamazepine, chloro and carboxylic acid 
in diclofenac) but remain O3-reactive, inferring the presence and position of the high e- 
density functional groups, such as the aromatic amine (diclofenac) and C=C double bond 
(carbamazepine) (Nakada et al., 2007), counteracts the inhibitory effect .   
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Ibuprofen possesses no electron-rich functional group and is recalcitrant towards O3-
treatment (Huber et al., 2005) however can be adequately removed through intense biological 
treatment (e.g. (Fick et al., 2011; Falås et al., 2012a, 2012b)). In addition, effective oxidative 
removal of O3-resistant APIs may be possible through the hydroxyl radical pathway 
(Antoniou et al., 2008).  
 
 
4. Conclusions  
 When the effect of O3 dose on degradation of 42 APIs in 6 different WWTP effluents 
was investigated, a large variability between APIs and effluents types was observed. 
 The estimated DDO3 of a specific API, used to evaluate the necessary O3 dose to 
achieve reduction by one decade, varied significantly among the effluents 
investigated.  
 DDO3 was correlated with the effluent DOC by calculating the DDO3/DOC for each 
API in every effluent. This enabled ranking of the different APIs into easily 
degradable, moderately degradable and recalcitrant to O3-treatment categories.  
 Following this practice, the required O3 dose can be predicted based on the target 
pharmaceutical and the matrix component of the wastewater (DOC) to be treated. 
 An O3 dose of 1.4 g per g DOC removed (by at least 90%) more than 80% of the APIs 
tested in this study. To remove the most O3-recalcitrant APIs a dose in the order of 2.4 
g O3 per g DOC is required. 
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